Abcellera Biologics Inc is trading at $5.51 (+5.11%) in pre-market sessions, driven by the appointment of Victor Sandor as an independent director and a broad risk-on sentiment across the equity markets for June 15, 2026. - The company announced on June 15, 2026, that Victor Sandor, M.D.C.M, a drug development and regulatory approval expert, has joined its board as an independent director, a move that has drawn investor attention. - The stock's performance also aligns with a wider market rally, as U.S. futures trend higher following an interim US-Iran peace deal and the NASDAQ Composite shows strong gains.